We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · January 04, 2022

No Benefit of Ipatasertib + Paclitaxel for PIK3CA/AKT1/PTEN-Altered HR+/HER2− Advanced Breast Cancer

Breast Cancer Research and Treatment

 

Additional Info

Breast Cancer Research and Treatment
Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial
Breast Cancer Res Treat 2021 Dec 03;[EPub Ahead of Print], N Turner, RA Dent, J O'Shaughnessy, SB Kim, SJ Isakoff, C Barrios, S Saji, I Bondarenko, Z Nowecki, Q Lian, SJ Reilly, H Hinton, MJ Wongchenko, B Kovic, A Mani, M Oliveira

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading